1800-272-662
Shopping Cart 0
countryflagAU
Login

Anatara Lifesciences Ltd

Healthcare AU ANR

0.01AUD
-(-%)

Last update at 2026-03-11T23:00:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.0040.02
LowHigh

Fundamentals

  • Previous Close 0.01
  • Market Cap3.16M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.30364M
  • Revenue TTM0.62M
  • Revenue Per Share TTM0.003
  • Gross Profit TTM -0.23083M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -1.95470M -2.07735M -2.02319M -2.53229M -1.99587M
Minority interest - - - - -
Net income -1.95470M -1.45124M -2.02319M -2.53561M -3.10420M
Selling general administrative 1.32M 1.35M 0.89M 1.38M 1.62M
Selling and marketing expenses - 0.00002M - - -
Gross profit -0.63397M -0.74891M - - -
Reconciled depreciation - 0.00246M 0.02M 0.02M 0.00626M
Ebit -1.95665M -1.45913M -2.02082M -2.52897M -1.99557M
Ebitda -1.95594M -1.45666M -1.99605M -2.50430M -1.98931M
Depreciation and amortization 0.00071M 0.00246M 0.02M 0.02M 0.00626M
Non operating income net other - - - - -
Operating income -1.95665M -1.45913M -2.02082M -2.52897M -1.99557M
Other operating expenses 2.93M 1.46M 3.28M 3.02M 3.11M
Interest expense 0.00742M - 0.00237M 0.00332M 0.00030M
Tax provision - 0.00000M 0.00000M 0.00000M 0.00000M
Interest income - 0.00788M 0.02M 0.00600M 0.00912M
Net interest income - 0.00788M 0.02M 0.00268M 0.00882M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.96946M -0.62610M 1.25M 0.00332M 1.11M
Total revenue 0.97M 0.64M - 0.00000M 0.00000M
Total operating expenses 1.32M 0.71M 3.28M 3.02M 3.11M
Cost of revenue 1.60M 0.75M - - -
Total other income expense net 0.00195M -0.61822M 1.25M -0.00332M -0.00030M
Discontinued operations - - - - -
Net income from continuing ops - -1.45124M -2.02319M -2.53229M -1.99587M
Net income applicable to common shares - - -2.02319M -2.53229M -1.99587M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 1.15M 1.67M 1.42M 1.77M 4.33M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.02M 0.02M 0.01M 0.02M 0.04M
Total liab 0.61M 0.31M 0.49M 0.40M 0.50M
Total stockholder equity 0.54M 1.36M 0.92M 1.36M 3.83M
Deferred long term liab - - - - -
Other current liab 0.03M 0.06M 0.42M 0.21M 0.21M
Common stock 24.15M 23.18M 21.37M 19.91M 19.76M
Capital stock - - 21.37M 19.91M 19.76M
Retained earnings -24.02777M -22.09007M -20.79188M -18.98366M -16.60401M
Other liab - - 0.00067M 0.00008M 0.03M
Good will - - - - -
Other assets - - - - -
Cash 0.10M 0.93M 0.35M 1.12M 3.43M
Cash and equivalents - - - - -
Total current liabilities 0.61M 0.30M 0.49M 0.36M 0.40M
Current deferred revenue - - - -0.02066M -0.01412M
Net debt 0.31M -0.93202M -0.35118M -1.05440M -3.35216M
Short term debt 0.41M - 0.00000M 0.02M 0.01M
Short long term debt - - - - -
Short long term debt total 0.41M - - 0.07M 0.08M
Other stockholder equity - - -0.57684M -0.92482M -3.15163M
Property plant equipment - - 0.00326M 0.07M 0.09M
Total current assets 1.15M 1.67M 1.42M 1.70M 4.24M
Long term investments - - - - -
Net tangible assets - - 0.92M 1.36M 3.83M
Short term investments - 0.05M 0.05M 0.05M 0.05M
Net receivables 1.03M 0.67M 1.00M 0.51M 0.77M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.17M 0.25M 0.08M 0.15M 0.20M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.42M 0.28M 0.35M 0.44M 0.68M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.00000M -0.00326M -0.06692M -0.08503M
Deferred long term asset charges - - - - -
Non current assets total 0.00008M 0.00079M 0.00326M 0.07M 0.09M
Capital lease obligations - - - 0.07M 0.08M
Long term debt total - - 0.00000M 0.05M 0.07M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - 0.05M -0.00173M -0.05000M -0.00398M
Change to liabilities - - 0.17M -0.03351M -0.07691M
Total cashflows from investing activities - 0.05M -0.00173M -0.05656M -0.00398M
Net borrowings - - -0.01819M -0.01744M -0.00051M
Total cash from financing activities 1.39M 1.83M 1.49M -0.02244M 2.85M
Change to operating activities - - -0.00793M -0.03057M -0.00668M
Net income -1.95470M -1.45124M -2.02319M -2.53229M -1.99587M
Change in cash -0.88075M 0.63M -0.76902M -2.31187M 0.75M
Begin period cash flow 0.98M 0.35M 1.12M 3.43M 2.68M
End period cash flow 0.10M 0.98M 0.35M 1.12M 3.43M
Total cash from operating activities -2.27200M -1.24740M -2.25790M -2.23288M -2.09748M
Issuance of capital stock - 1.99M 1.70M - 3.03M
Depreciation 0.00071M 0.00246M 0.02M 0.02M 0.00626M
Other cashflows from investing activities - 0.05M 0.00000M -0.05000M 0.00000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.35720M 0.33M -0.49555M 0.26M -0.14223M
Sale purchase of stock 1.09M -0.15701M -0.18868M -0.00500M -0.18069M
Other cashflows from financing activities -0.10325M 0.05M -0.01819M -0.01744M -0.00051M
Change to netincome - - 0.07M 0.07M 0.12M
Capital expenditures 0.00000M 0.00000M 0.00173M 0.00656M 0.00398M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.37117M 0.34M -0.49555M 0.26M -0.14223M
Stock based compensation 0.09M 0.03M 0.05M 0.07M 0.12M
Other non cash items -0.03184M -0.17042M -0.25947M 0.27M -0.10787M
Free cash flow -2.27200M -1.24740M -2.25962M -2.23944M -2.10146M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ANR
Anatara Lifesciences Ltd		 - -% 0.01 - - 5.07 2.80 2.18 -1.018
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral medication to assist weight reduction and control. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.

Anatara Lifesciences Ltd

81 Flinders Street, Adelaide, SA, Australia, 5000

Key Executives

Name Title Year Born
Dr. David Lionel Brookes FACRRM, FAICD, MBBS Exec. Chairman 1960
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. Chief Operations Officer NA
Jane Lowe Managing Director of IR Department NA
Mr. Simon Erskine Chief Devel. Officer NA
Dr. Stephen Denaro AGIA, BCom, CA, GradDipApp CG, MAICD Company Sec. NA
Ms. Hayley van der Meer B Biomed Sc, Grad Dip Marketing Management Commercial Mang. NA
Dr. David Lionel Brookes F.A.C.I.D., FACRRM, FAICD, MBBS Executive Chairman 1960
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. COO & Executive Director NA
Mr. Simon Erskine Chief Development Officer NA
Dr. Stephen Denaro AGIA, BCom, CA, GradDipApp CG, MAICD Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.